NOTCH1 and cancer: The antibody OMP21M18, a humanized IgG2 antibody, blocking the interaction of DLL4 with NOTCH1 and NOTCH4 and had been tested as a cancer stem cell agent in a Phase-I trial in patients with previously treated solid tumors [290] (Figure 3).